Dentist dies of cardiac issue

Behjath Hussain, a dentist, who had been kidnapped for ransom by his relatives and rescued by Cyberabad police two weeks ago, died of massive heart stroke on Wednesday.

Rajendra Nagar Assistant Commissioner of Police K Ashok Chakravarthy said that for the past one week the dentist had not been keeping well and two days ago he was admitted in a private hospital.

“On Wednesday morning, he suffered massive heart and died while he was being taken to a hospital,” he said.

His funeral was performed by the family members at a graveyard in Hussaini Alam area in the old city. On October 27, the dentist, who was also a realtor, was kidnapped for a ransom of ₹10 crore in bitcoins. When rescued, Hussain’s nails were cut and injuries were found on his face and head.

Source Article

Read More

Admissions to cardiac care unit double in Lebanon amid medicine shortages

Admissions to Lebanon’s cardiac care unit doubled in late October as the country struggles from shortages of medicine, an economic crisis, and the ongoing coronavirus pandemic.

Key medicines have been in short supply as people rushed to stockpile them following reports that the Central Bank of Lebanon planned to lift subsidies on medicines because it no longer has enough foreign exchange reserves to maintain its import subsidy scheme.

For more coronavirus news, visit our dedicated page.

Patients have subsequently found themselves at risk as they are unable to access potentially life-saving treatments.

Admissions to the Cardiac Care Unit at Beirut’s Rafic Hariri University Hospital (RHUH) have doubled recently, tweeted the hospital’s CEO Firass Abiad, who said patients with heart failure have been unable to find needed medications including Furosemide, an inexpensive diuretic.

Heart patients suffer from loss of medicine access

In recent weeks, heart patients have reported increasing concerns related to ongoing shortages of the two types of cardiovascular medicines. One of them is a medicine manufactured locally with a license from a French laboratory, the other a multivitamin specially formulated to help lower cholesterol levels for a healthy heart.

“Heart patients in Lebanon are at the front line of this issue and are complaining of the loss of two types of medicines,” Nabil Shasha, Head of Cardiology Divison at RHUH told Al Arabiya English.

“Some of these medications are very crucial in a sense that stopping any of them for few days could subject patients to a wide range of complications that could jeopardize their lives,” he explained. adding that patients with coronary artery disease might sustain acute myocardial infarction or cardiac death if they fail to take anti-platelets.

“Lack of diuretic drugs that excrete fluids through the kidneys and increase urine output. If not taken, the patient’s body starts accumulating fluids leading to volume overload causing lung congestion and shortness of breath and ankle and leg swelling.” Hadi Skouri, Cardiologist at AUBMC told Al Arabiya English.

“The patient starts to feel short of breath at rest and with time it progresses to shortness of breath at rest their oxygen levels start to be reduced and he will be admitted to the emergency room and hospital admission to receive intravenous diuretics,” he added.

Drug companies rationing medicines

Pharmaceutical companies in Lebanon have been rationing the distribution of drugs among pharmacies after Lebanon’s Central Bank Governor Riad Salameh said subsidies would have to stop once the threshold for obligatory foreign exchange reserves was reached, without suggesting a timeframe.

According to a Lebanese official quoted by Reuters in early October, the country has only around $1.8 billion of its foreign exchange reserves remaining available for subsidizing key food and other imports.


Read More

Cardiac MRI contrast agents unlikely to produce adverse reactions, study finds

Oct. 29 (UPI) — Chemicals used to improve images of the heart during MRI scans are unlikely to produce allergic reactions and other side effects in patients who take them, according to a study published Thursday by the journal Radiology: Cardiothoracic Imaging.

In reviewing data from more than 145,000 cardiac MRI scans performed in Europe between 2017 and 2019, well under 1% included reports of side effects or allergic reactions related to the use of contrast agents such as gadolinium, the data showed.

In addition, just 47 of the contrast agent-related adverse reactions included those that were “severe” in nature, such as chest pain, the researchers said.

“Our study demonstrates that the administration of intravenous gadolinium-based contrast agents for cardiac MRI is safe for the overwhelming majority of patients,” study co-author Dr. Johannes Uhlig said in a statement.

Cardiac MRI is used to diagnose a variety of conditions, including aneurysms, blood clots and defects. The imaging method also can help evaluate diseases such as cardiomyopathy and myocarditis, or inflammation of the heart.

The majority of cardiac MRI exams use intravenous gadolinium-based contrast agents to improve visualization of the heart muscle and blood flow, the researchers said.

Contrast agents contain an ion of the heavy metal gadolinium, which is toxic to humans. However, in contrast agents, it is bound in a molecule called a ligand to make it safe, according to Uhlig, a cardiologist at University Medical Center in Goettingen, Germany.

The findings of this study come three years after the European Union enacted new regulations restricting the marketing of linear gadolinium-based contrast agents, he and his colleagues said.

Gadolinium-based contrast agents are classified as either linear — with longer ligands — or macrocyclic — with a cage-shaped ligand that traps the ion inside — based on the type of ligand used, they said.

Studies have shown that trace amounts of the toxic gadolinium ions may remain in the body following repeated gadolinium-based contrast agent use, and linear agents are thought to have a higher likelihood of staying behind compared to macrocyclic ones, according to Uhlig.

The U.S. Food and Drug Administration recommends that physicians consider gadolinium retention when choosing agents to use, he said.

For the new study, Uhlig and his colleagues reviewed data on 154,779 patients who underwent cardiac MRI, with almost 95%, or 145,855, receiving gadolinium-based contrast agents.

Among those who received these agents prior to cardiac MRI, 0.38%, or 556, reported an adverse reaction, with all but 47 being classified as “mild.” Those included allergic reactions such as developing hives and wheezing, the data showed.

The 47 “moderate” or “severe” adverse reactions included chest pain and irregular heartbeat. Adverse events also occurred in cardiac MRIs performed without gadolinium, with 2.6%, or 231, of the 8,924 patients reporting adverse reactions such as anxiety and shortness of breath, the researchers said.

The results underscore the importance of preprocedural assessments to look for contraindications to MRI scanning and use of gadolinium-based contrast agents, as well as the likelihood of adverse

Read More